AK3280

· Shanghai Ark Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AK3280, covering 2022-07-20 to 2022-07-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]